期刊文献+

益生菌制剂对儿童反复呼吸道感染的疗效和免疫功能影响的系统评价 被引量:10

Clinical efficacy of probiotics for recurrent respiratory tract infections of children and its influence on immune function: a systematic review
原文传递
导出
摘要 目的系统评价益生菌制剂防治儿童反复呼吸道感染(RRTIs)的有效性和安全性,为临床提供循证参考。方法计算机检索Pub Med、EMBase、Cochrane图书馆、中国生物医学文献数据库(CBM)、中国学术期刊全文数据库(CNKI)、维普中文期刊全文数据库(VIP)和万方数据库,收集益生菌制剂(试验组)防治儿童RRTIs的随机对照试验(RCT),检索时限均为建库起至2019年3月。提取资料,用Rev Man 5.3软件进行Meta-分析。结果共纳入12项研究,878例患者。Meta-分析结果显示,试验组在总有效率[RR=1.31,95%CI(1.22,1.41),P<0.001]、抗菌药用药时间[MD=-4.42,95%CI(-5.92,-2.91),P<0.001]、年呼吸道感染次数[MD=-2.30,95%CI(-2.70,-1.89),P<0.001]、临床体征改善时间均优于对照组(P<0.05);免疫球蛋白Ig G[MD=1.80,95%CI(1.60,2.01),P<0.001]、Ig A[MD=0.37,95%CI(0.23,0.51),P<0.001]、Ig M[MD=0.06,95%CI(0.02,0.09),P=0.002],T淋巴细胞亚群CD3^+[MD=4.48,95%CI(1.48,7.49),P=0.03]、CD4^+[MD=3.17,95%CI(1.01,5.55),P=0.009]和CD8^+[MD=-4.44,95%CI(-6.52,-2.36),P<0.05]改善情况均显著优于对照组,差异均有统计学意义(P<0.05)。结论益生菌可有效治疗儿童反复呼吸道感染,安全性较好。但由于纳入研究数量少,研究质量不统一,尚需要大样本、高质量的临床随机对照研究予以证实。 Objective To evaluate the efficacy and safety of probiotics for recurrent respiratory tract infections(RRTIs)of children,and to provide evidence-based reference for clinic.Methods Retrieved from Pub Med,EMBase,Cochrane Library,CBM,CNKI,Wanfang database and VIP database,randomized controlled trials(RCTs)about probiotics(trail group)vs.non-probiotics(control group)for RRTIs of children were collected during database establishment to January 2018.After literature scanning and data extraction,the risk of bias of included trials were evaluated by using Cochrane 5.1.0 risk bias evaluation tool.Meta-analysis was performed by using Rev Man 5.3 software.Results A total of 12 RCTs involving 878 children were included.The results showed that the trial group was superior to control group in total response rate[RR=1.31,95%CI(1.22,1.41),P<0.001],the time of antibiotics use[MD=-4.42,95%CI(-5.92,-2.91),P<0.001],respiratory infections per year[MD=-2.30,95%CI(-2.70,-1.89),P<0.001],clinical symptom improvement time;improvement of Ig G[MD=1.80,95%CI(1.60,2.01),P<0.001],Ig A[MD=0.37,95%CI(0.23,0.51),P<0.001],Ig M[MD=0.06,95%CI(0.02,0.09),P=0.002];T lymphocyte subset of CD3^+[MD=4.48,95%CI(1.48,7.49),P=0.03],CD4^+[MD=3.17,95%CI(1.01,5.55),P=0.009]and CD8^+[MD=-4.44,95%CI(-6.52,-2.36),P<0.001]than that of in control group,the difference were statistically significant(P<0.05).Conclusions The current evidence shows that probiotics can reduce the frequencv of recurrent respiratory infection with safety.However,due to the number and quality of included studies,more large-scale and high-quality RCTs are needed.
作者 夏雯 柯灵芝 利莉 卫国 徐凤 XIAWen;KE Lingzhi;LI Li;WEI Guo;XU Feng(Department of Pediatrics,Huangshi Central Hospital,Edong Medical Group,Huangshi 435000,China)
出处 《药物评价研究》 CAS 2020年第1期140-146,共7页 Drug Evaluation Research
关键词 益生菌 儿童反复呼吸道感染 免疫功能 META-分析 Key wors:probiotics recurrent respiratory tract infections of child immune function Meta-analysis
作者简介 第一作者:夏雯,女,本科,主管护师,研究方向为儿科临床护理。Tel:17762722512 E-mail:31328932@qq.com;通信作者:柯灵芝,女,本科,副主任护师,研究方向为儿科临床护理、循证医学。Tel:13972773900 E-mail:64042494@qq.com
  • 相关文献

参考文献19

二级参考文献146

共引文献560

同被引文献212

引证文献10

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部